Fujirebioさんが再投稿しました
We're #hiring a new Senior Manufacturing Technician in Sunnyvale, California. Apply today or share this post with your network.
Fujirebio is is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.
Fujirebioの外部リンク
📰 Fujirebio announced today the submittal of FDA regulatory filing for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test as an aid to identify patients with Amyloid pathology associated with Alzheimer's disease - Expected to be the first commercially-available blood-based in-vitro diagnostic test for patients being assessed for Alzheimer’s disease in the US. Read more here 👉 https://bit.ly/3zH4I0p
Fujirebioさんが再投稿しました
🌎 Today on #WorldAlzheimersDay we join many others in raising awareness for Alzheimer’s disease. ADx keeps exploring new fluid biomarkers while expanding our Tau and Synaptic marker panels, facilitating and contributing to Alzheimer’s research. Watch our video that summarizes the advancements through the years. 🎥 Together, we can make a difference! 💜 #AlzheimersAwareness #FluidBiomarkers #ADxNeuroSciences
Fujirebioさんが再投稿しました
Join Our Team as a Business Officer! 📋 Do you want to play a crucial role in coordinating and managing contract work to support our growing global business with pharma and IVD companies? 🤝 Would you like to act as a liaison between the ADx team and our valuable network of partners? 🧠 Do you thrive in a dynamic environment and want to be part of an enthusiastic team specialized in the Neuro field? If so, we invite you to apply for our Business Officer position: https://lnkd.in/e9C6Wteh Take the next step in your career and become an integral part of our innovative team! 🌟
Fujirebioさんが再投稿しました
Aquí estamos, en una nueva sesión de la #ADLM para darle la bienvenida a todos nuestros clientes y distribuidores de Latinoamérica; visítenos en el booth #1032, para conversar sobre las novedades que #Fujirebio tiene para su laboratorio: pruebas de neuro para detección de #Alzheimer, genotipado de #HPV, pruebas confirmatorias, entre otras. ¡te esperamos!
📰 Biogen, Beckman Coulter and Fujirebio announced today a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD). Through this collaboration, the companies will work to identify new blood-based biomarkers and advance known blood-based biomarkers for tau pathology in AD. Read more here 👉 https://lnkd.in/gzr3q8et